Provectus Biopharmaceuticals has filed a notice of an exempt offering of securities to raise $10 Million in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Provectus Biopharmaceuticals is raising up to $10,000,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Heather Raines played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.
To learn more about Provectus Biopharmaceuticals, visit http://www.provectusbio.com/
Provectus Biopharmaceuticals Linkedin Page: https://www.linkedin.com/company/provectus-biopharmaceuticals/
Contact:
Heather Raines, Chief Financial Officer
866-594-5999
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.